Psoriasis Treatment: Topicals, Phototherapy, Tablets and Biologics

Dr Jonas Witt

Medical Doctor

6 min

•

September 28, 2026

Key takeaways

There is no single best psoriasis treatment for everyone.
Topical medicines are common for limited disease.
Phototherapy and systemic medicines are options when psoriasis is more extensive or impactful.
Treatment choice should account for health history, body site, safety and personal preferences.

Psoriasis Treatment: Topicals, Phototherapy, Tablets and Biologics

How treatment is chosen

Psoriasis treatment is matched to the pattern and impact of disease. Clinicians consider body surface area, difficult sites such as the scalp or genitals, nail and joint involvement, previous response, other conditions, pregnancy plans, convenience and personal preferences.

Topical treatments

Topical corticosteroids are widely used for plaque psoriasis. Vitamin D analogues, tazarotene and calcineurin inhibitors may be used in particular situations, sometimes with corticosteroids. Emollients can soften scale and reduce dryness. Potency and duration matter, especially on the face, skin folds and genitals.

Phototherapy

Narrowband UVB is an established treatment for suitable people with more extensive psoriasis. It is different from commercial tanning beds. Phototherapy requires controlled dosing and a treatment schedule, with benefits and risks discussed by a dermatologist.

Oral systemic medicines

Systemic options include medicines such as methotrexate, ciclosporin, acitretin, apremilast, fumarates in some countries and newer targeted oral medicines. Each has different contraindications, laboratory requirements and pregnancy considerations.

Biologic medicines

Biologics target specific inflammatory pathways such as TNF, IL-17 or IL-23. They can be highly effective for moderate-to-severe psoriasis, but choice depends on medical history, infections, comorbidities, prior treatments, access and patient preferences.

What treatment success can mean

Treatment goals are not only about visible clearance. Itch, pain, sleep, function, confidence and treatment burden matter too. If a treatment is difficult to use consistently or is not meeting agreed goals, that is useful information to bring to the prescribing clinician.

Every effective medicine has a safety profile. Topical corticosteroids need appropriate strength and duration, phototherapy involves controlled ultraviolet exposure, and systemic medicines may require screening or laboratory follow-up. The purpose of follow-up is to balance benefit, side effects and practical burden over time.

Safety and follow-up

The same percentage of affected skin can have very different consequences depending on location. Psoriasis on the hands or feet can interfere with work and walking; genital or facial psoriasis can have a large emotional impact; scalp and nail disease can be particularly persistent. Guidelines therefore consider site and quality-of-life impact, not only total skin area.

Shared decision-making in psoriasis care

Treatment decisions often involve trade-offs. A person may prioritise rapid skin clearance, avoiding injections, pregnancy planning, fewer laboratory visits or a treatment that fits travel and work. Guidelines provide evidence-based options, but the practical choice still depends on the individual. Explaining what matters most to you can help the clinical conversation focus on outcomes that are meaningful in daily life.

How do doctors decide when to move beyond creams?

Treatment is not escalated by surface area alone. Clinicians also consider symptoms, high-impact sites, nail or joint involvement, quality of life, previous treatment and whether topical treatment is practical. Psoriasis on the hands, feet, face, genitals or scalp can have a major impact even when the affected area is small. Phototherapy or systemic treatment may therefore be considered when topical treatment is insufficient or the overall burden is high.

What monitoring can systemic psoriasis treatment require?

Monitoring depends on the medicine. Some conventional systemic treatments require blood counts and liver or kidney tests. Before certain biologics, clinicians may review vaccination history and screen for infections such as tuberculosis or hepatitis according to local guidance. Pregnancy plans, other medicines and existing health conditions can also affect treatment choice. These checks support safe prescribing; they do not mean every treatment carries the same risks.

The most useful way to think about psoriasis treatment is to separate what is well established from what varies between people. Psoriasis can change over time, and symptoms, body sites, treatment response and daily impact are not identical from one person to another. Use educational information to understand the terms you encounter and to prepare specific questions. If the pattern changes, symptoms become difficult to manage, or you are unsure whether a new symptom is related to psoriasis, a healthcare professional can assess it in the context of your history and current treatment.

Conventional systemic treatments

Conventional systemic medicines act throughout the body and can be used when psoriasis is extensive, high impact or insufficiently controlled with topical treatment. Examples include methotrexate, ciclosporin and acitretin, although availability and use vary by country and individual circumstances. These medicines have different benefits, contraindications and monitoring requirements. They should therefore be understood as distinct options rather than one interchangeable category.

Biologics and targeted treatments

Biologic medicines target specific inflammatory signals involved in psoriasis, including TNF, IL-17 and IL-23 pathways. Targeted oral medicines act on other intracellular or immune pathways. These treatments can achieve substantial skin improvement for many people with moderate-to-severe disease, but response varies. Infection history, other inflammatory conditions, pregnancy considerations, previous therapies, dosing preferences and access can all influence which option is appropriate.

Treatment success judged

Clinical studies often use measures such as PASI response, but everyday success can also mean less itch, fewer cracks, better sleep, easier movement or less time spent applying treatment. Agreeing on the goal helps make follow-up more useful. If a medicine improves most plaques but one difficult site remains active, that may call for a site-specific adjustment rather than assuming the entire treatment has failed.

How mama health can support you

mama health is a free app for everything your condition asks of you, grounded in medical science and the experience of others, so you do not have to figure it out alone.

Use mama health to understand your labs in simple terms, upload and organise your health documents, find local care and specialists, and ask questions with answers grounded in medical science. You can also learn from the experiences of other people living with psoriasis, giving you practical context alongside evidence-based information.

Frequently asked questions

The answers below address common practical questions about this topic. They are intended to explain general evidence and terminology. Individual symptoms can have more than one cause, and the relevance of a treatment, test or risk factor depends on the wider health context.